A combination of the immunohistochemical markers CK7 and SATB2 is highly sensitive and specific for distinguishing primary ovarian mucinous tumors from colorectal and appendiceal metastasesNicola S. Meagher, Raghwa Sharma, Linyuan Wang et al.|Modern Pathology|2019Cited by 104
Drug-regulated CD33-targeted CAR T cells control AML using clinically optimized rapamycin dosingJacob Appelbaum, Michael C. Jensen, Kaori Oda et al.|Journal of Clinical Investigation|2024Cited by 51
MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinomaEun Young Kang, Alexander Hein, Joshua Millstein et al.|Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin|2021Cited by 23
A Phase 1 Study of CFT7455, a Novel Degrader of IKZF1/3, in Multiple Myeloma and Non-Hodgkin LymphomaJesús G. Berdeja, Sagar Lonial, Sikander Ailawadhi et al.|Blood|2021Cited by 22
Getting the MOST out of follow-up: a randomized controlled trial comparing 3 monthly nurse led follow-up via telehealth, including monitoring CA125 and patient reported outcomes using the MOST (Measure of Ovarian Symptoms and Treatment concerns) with routine clinic based or telehealth follow-up, after completion of first line chemotherapy in patients with epithelial ovarian cancerPaul A. Cohen, Michael Friedländer, Penelope M. Webb et al.|International Journal of Gynecological Cancer|2021Cited by 12